XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015

XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the results from its Phase 1 first-in-human study of XOMA 358, an allosteric modulating monoclonal antibody that binds to insulin receptors and attenuates insulin action, will be presented at the Endocrine Society's 97th Annual Meeting, taking place from March 5-8, 2015, in San Diego, California.

The details of the presentation are included below:

Title: XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial

Session: LBS 097-116-Late-breaking Diabetes & Glucose Metabolism III

Date: Saturday, March 7, 2015

Time: 1:00 – 3:00pm PT

Presenter: Rajneesh Nath, PhD, Vice President, Clinical Science at XOMA

Location: LBS-104 (Hall D-F, Diabetes)

About XOMA 358

Insulin is the major hormone for lowering blood glucose levels. Abnormal increases in insulin secretion can lead to profound hypoglycemia (low blood sugar), a state that can result in significant morbidities including cerebral damage and epilepsy. In some instances, profound hypoglycemia can be fatal. XOMA 358 is a fully human allosteric modulating monoclonal antibody that binds to insulin receptors and attenuates insulin action. XOMA 358 is being investigated as a novel treatment for non-drug-induced, endogenous hyperinsulinemic hypoglycemia (low blood glucose caused by excessive insulin production) and other related disorders. A therapy that safely and effectively mitigates insulin-induced hypoglycemia has the potential to address a significant unmet therapeutic need for certain rare medical conditions associated with hyperinsulinism.

About XOMA Corporation

XOMA's innovative product candidates are the result of the Company's expertise in developing ground-breaking monoclonal antibodies, including allosteric modulating antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program for Behçet's disease uveitis, non-infectious uveitis and pyoderma gangrenosum. XOMA's scientific research also produced the XMet program, which consists of three classes Selective Insulin Receptor Modulators (SIRMs) antibodies. XOMA 358, the lead antibody in the XMetD program, is a first-in-class allosteric modulating monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, which could have a major effect on the treatment of abnormal metabolic states.

More detailed information can be found at www.xoma.com.

CONTACT: Company and Investor Contacts:
         Ashleigh Barreto
         510-204-7482
         [e-mail]
         
         Juliane Snowden
         The Oratorium Group, LLC
         [e-mail]